<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425473</url>
  </required_header>
  <id_info>
    <org_study_id>Z191100006619067</org_study_id>
    <nct_id>NCT04425473</nct_id>
  </id_info>
  <brief_title>Esketamine and Perioperative Depressive Symptoms</brief_title>
  <official_title>Effect of Esketamine on Perioperative Depressive Symptoms in Patients Undergoing Major Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative depressive symptoms (PDS) are common in population undergoing surgery, and this
      would be sharpened especially for complicated, high-risk major surgery. However, None of
      treatments could resolve this clinical problem during limited perioperative period. The
      remarkable effects of ketamine on treatment resistant depression have been verified by
      several clinical trials and the enantiomer S-ketamine (esketamine) showed similar
      antidepressant efficacy with better safety in recent studies. The efficacy and safety of
      esketamine administrated intra-operatively for PDS will be verified in this study. Other
      secondary outcomes such as anxiety, postoperative pain and psychiatric symptoms will also be
      investigated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptoms remission</measure>
    <time_frame>Postoperative 3-day</time_frame>
    <description>Remission is defined as a score no more than 10 of the MADRS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Depression Symptoms</condition>
  <condition>Esketamine</condition>
  <condition>Perioperative Complication</condition>
  <condition>Major Surgery</condition>
  <arm_group>
    <arm_group_label>esketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>Esketamine will be administrated intravenously at skin incision, with total dose of 0.5mg/kg and continuous infusion for 40 minutes.</description>
    <arm_group_label>esketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be administrated intravenously at skin incision, with total dose of 0.5ml/kg and continuous infusion for 40 minutes.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing elective major surgery

          -  Ages between 18 and 65 years old

          -  Moderate to severe depressive symptoms ( the Patient Health Questionnaire-9 scores
             equal to or more than 10 and Montgomery-Åsberg Depression Rating Scale scores equal to
             or more than 22 )

        Exclusion Criteria:

          -  Patients with American Society of Anesthesiologists grade V

          -  Body Mass Index more than 30 kg/㎡

          -  Laboratory evidence of hormone levels disorder due to primary diseases

          -  Patients with other psychiatric illness

          -  Patients can not cooperate to complete psychiatric assessments

          -  Major depressive disorder patients receiving antidepressants within the past 2 weeks

          -  Pregnant or breast-feeding woman

          -  Drug abused history

          -  Refused to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <phone>8610-59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing TianTan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yuming Peng</investigator_full_name>
    <investigator_title>Vice Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

